Aleix Prat, Director at Clinic Barcelona Comprehensive Cancer Center, Chief Scientific Officer at Reveal Genomics, shared a post on LinkedIn about a recent article he and colleagues authored:
“New publication in Nature Medicine
Proud to be part – together with Dr. Maria Vidal at Clínic Barcelona Comprehensive Cancer Center, of this landmark international study recently published in Nature Medicine, led by Dr. Shanu Modi at Memorial Sloan Kettering Cancer Center.
This updated analysis, with more than 32 months of follow-up, confirms the durable overall survival benefit of Trastuzumab deruxtecan (T-DXd) versus physician’s choice chemotherapy in patients with HER2-low metastatic breast cancer, reinforcing its role as a standard of care in this population.
It’s inspiring to see how the HER2 landscape continues to evolve – moving beyond traditional HER2-positive disease – and to contribute, from our site, to studies that redefine precision oncology for breast cancer.
Grateful to all investigators, patients, and collaborators who made this trial possible.”
Title: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Authors: Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Wei Li, Junji Tsurutani, Naoto T. Ueno, Khalil Zaman, Aleix Prat, Konstantinos Papazisis, Hope S. Rugo, Toshinari Yamashita, Nadia Harbeck, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Xiaojia Wang, Andrea Gombos, Eriko Tokunaga, Cecilia Orbegoso Aguilar, Lotus Yung, Feng Xiao, Yingkai Cheng, David Cameron
Read the Full Article in Nature Medicine.
More posts featuring Aleix Prat on OncoDaily.